Brookfield Corp’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brookfield Corp’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-180,000	Closed	-$18.5M	–	578
2023 Q2	$18.5M	Sell	180,000 -20,000	-10%	-$2.11M	0.07%	99
2023 Q1	$21.8M	Buy	200,000 +117,500	+142%	+$13M	0.08%	98
2022 Q4	$9.39M	Sell	82,500 -3,473	-4%	-$288K	0.04%	159
2022 Q3	$5.32M	Buy	85,973 +21,283	+33%	+$1.49M	0.02%	268
2022 Q2	$5.16M	Sell	64,690 -51,494	-44%	-$4.88M	0.02%	249
2022 Q1	$12.2M	Buy	116,184 +36,075	+45%	+$3.52M	0.05%	132
2021 Q4	$8.63M	Buy	80,109 +11,331	+16%	+$1.24M	0.03%	142
2021 Q3	$7.53M	Buy	+68,778	New	+$7.14M	0.03%	170

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Brookfield Corp's HZNP Position: Q3 2023 in Review

Brookfield Corp sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 180,000 shares — an estimated $18.5M sold.

Brookfield Corp first reported a position in HZNP in Q3 2021 and held it in 8 quarters. The position peaked at $21.8M in Q1 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Brookfield Corp reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Brookfield Corp sold 180,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $18.5M.
Brookfield Corp first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 8 quarters.
Brookfield Corp's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $21.8M in Q1 2023.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.